Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order